Testing NF-kB-based therapy in hemiparkinsonian monkeys

Journal of Neuroimmune Pharmacology

Volumn 7, Issue 3, 2012, Pages 544-556

  Mondal, Susanta ^a   Roy, Avik ^a   Jana, Arundhati ^a   Ghosh, Sankar ^b   Kordower, Jeffrey H ^a   Pahan, Kalipada ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Dopamine; Dopaminergic neurons; Monkey; Motor function; NF kB; Parkinson's disease

Indexed keywords

I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NEUROPROTECTIVE AGENT; NEUROTRANSMITTER; NUCLEAR FACTOR KAPPA B ESSENTIAL MODIFIER BINDING DOMAIN; UNCLASSIFIED DRUG; I KAPPA B KINASE; IKBKG PROTEIN, HUMAN; NBD PEPTIDE, MOUSE; PEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; MOTOR PERFORMANCE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; GENETICS; METABOLISM; MOLECULAR GENETICS; RHESUS MONKEY;

AMINO ACID SEQUENCE; ANIMALS; FEMALE; I-KAPPA B KINASE; MACACA MULATTA; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PARKINSONIAN DISORDERS; PEPTIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866080814     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-012-9377-9     Document Type: Article

References (27)

1. Collier TJ, Kanaan NM, Kordower JH (2011) Ageing as a primary risk factor for Parkinson's disease: evidence from studies of nonhuman primates. Nat Rev Neurosci 12:359-366
2. Collier TJ, Steece-Collier K, Kordower JH (2003) Primate models of Parkinson's disease. Exp Neurol 183:258-262 (Pubitemid 37205067)
3. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909 (Pubitemid 37130207)
4. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB (2000) Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 74:2213-2216 (Pubitemid 30217680)
5. Emborg ME, Shin P, Roitberg B, Sramek JG, Chu Y, Stebbins GT, Hamilton JS, Suzdak PD, Steiner JP, Kordower JH (2001) Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp Neurol 168:171-182 (Pubitemid 32195269)
6. Gao HM, Liu B, Zhang W, Hong JS (2003) Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 24:395-401 (Pubitemid 36952555)
7. Ghosh S, Hayden MS (2008) New regulators of NF-kappaB in inflammation. Nat Rev Immunol 8:837-848
8. Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl):S81-96
9. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE, Pahan K (2007) Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 104:18754-18759 (Pubitemid 350210769)
10. Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K (2009) Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci 29:13543-13556
11. Gibbs RA et al (2007) Evolutionary and biomedical insights from the rhesus macaque genome. Science 316:222-234 (Pubitemid 46633091)
12. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A (2006) Genetics of Parkinson's disease and parkinsonism. Ann Neurol 60:389-398 (Pubitemid 44684974)
13. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132:344-362
14. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72:355-363 (Pubitemid 26111202)
15. Jana A, Pahan K (2010) Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease. J Neurosci 30:12676-12689
16. Khasnavis S, Pahan K (2012) Sodium benzoate, a metabolite of cinnamon and a food additive, upregulates neuroprotective parkinson disease protein DJ-1 in astrocytes and neurons. J Neuroimmune Pharmacol 7:424-435
17. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767-773
18. Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell J 3rd, Gasmi M, Bartus RT (2006) Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60:706-715 (Pubitemid 46048488)
19. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S (2000) Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289:1550-1554
20. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 211:13-16 (Pubitemid 26228016)
21. Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl:277-290 (Pubitemid 32037200)
22. Olanow CW, Tatton WG (1999) Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22:123-144 (Pubitemid 29144883)
23. Qureshi GA, Baig S, Bednar I, Sodersten P, Forsberg G, Siden A (1995) Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. Neuroreport 6:1642-1644
24. Roy A, Pahan K (2011) Prospects of statins in Parkinson disease. Neuroscientist 17:244-255
25. Saha RN, Pahan K (2006) Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid Redox Signal 8:929-947 (Pubitemid 44036510)
26. Saha RN, Liu X, Pahan K (2006) Up-regulation of BDNF in astrocytes by TNF-alpha: a case for the neuroprotective role of cytokine. J Neuroimmune Pharmacol 1:212-222 (Pubitemid 44244127)
27. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP (2006) Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J 20:670-682 (Pubitemid 44933311)